Diagnostic Value of Preoperative CA125, LDH and HE4 for Leiomyosarcoma of the Female Reproductive System

References

• Vujosevic S, Krnjevic D, Bogojevic M, et al. Primary leiomyosarcoma of the thyroid gland with prior malignancy and radiotherapy: a case report and review of literature. World J Clin Cases. 2019;7(4):473–481. doi:10.12998/wjcc.v7.i4.47330842958
   PubMed Web of Science ®Google Scholar
• Mbatani N, Olawaiye AB, Prat J. Uterine sarcomas. Int J Gynaecol Obstet. 2018;143(Suppl 2):51–58. doi:10.1002/ijgo.1261330306577
   PubMed Web of Science ®Google Scholar
• Gockley AA, Rauh-Hain JA, Del Carmen MG. Uterine leiomyosarcoma: a review article. Int J Gynecol Cancer. 2014;24(9):1538–1542. doi:10.1097/IGC.000000000000029025304676
   PubMed Web of Science ®Google Scholar
• Juhasz-Boss I, Gabriel L, Bohle RM, Horn LC, Solomayer EF, Breitbach GP. Uterine Leiomyosarcoma. Oncol Res Treat. 2018;41(11):680–686. doi:10.1159/00049429930321869
   PubMed Web of Science ®Google Scholar
• Giuliani E, As-Sanie S, Marsh EE. Epidemiology and management of uterine fibroids. Int J Gynaecol Obstet. 2020;149(1):3–9. doi:10.1002/ijgo.1310231960950
   PubMed Web of Science ®Google Scholar
• Li HM, Liu J, Qiang JW, Zhang H, Zhang GF, Ma F. Diffusion-weighted imaging for differentiating uterine leiomyosarcoma from degenerated leiomyoma. J Comput Assist Tomogr. 2017;41(4):599–606. doi:10.1097/RCT.000000000000056527997438
   PubMed Web of Science ®Google Scholar
• Okizuka H, Sugimura K, Takemori M, Obayashi C, Kitao M, Ishida T. MR detection of degenerating uterine leiomyomas. J Comput Assist Tomogr. 1993;17(5):760–766. doi:10.1097/00004728-199309000-000188370831
   PubMed Web of Science ®Google Scholar
• Sun S, Bonaffini PA, Nougaret S, et al. How to differentiate uterine leiomyosarcoma from leiomyoma with imaging. Diagn Interv Imaging. 2019;100(10):619–634. 10.1016/j.doi.2019.07.00731427216
   PubMed Web of Science ®Google Scholar
• Nagamatsu A, Umesaki N, Li L, Tanaka T. Use of 18F-fluorodeoxyglucose positron emission tomography for diagnosis of uterine sarcomas. Oncol Rep. 2010;23(4):1069–1076. doi:10.3892/or_0000073420204293
   PubMed Web of Science ®Google Scholar
• Food and Drug Administration. Laparoscopic uterine power morcellation in hysterectomy and myomectomy: FDA safety communication. Available from: https://www.fda.gov/MedicalDevices/Safety/AlertsandNotices/ucm393576.htm. Accessed 1124, 2014.
   Google Scholar
• Weiland F, Fritz K, Oehler MK, Hoffmann P. Methods for identification of CA125 from ovarian cancer ascites by high resolution mass spectrometry. Int J Mol Sci. 2012;13(8):9942–9958. doi:10.3390/ijms1308994222949840
   PubMed Web of Science ®Google Scholar
• Kim HS, Han KH, Chung HH, et al. Neutrophil to lymphocyte ratio for preoperative diagnosis of uterine sarcomas: a case-matched comparison. Eur J Surg Oncol. 2010;36(7):691–698. doi:10.1016/j.ejso.2010.05.00420570475
   PubMed Web of Science ®Google Scholar
• Moore RG, Hill EK, Horan T, et al. HE4 (WFDC2) gene overexpression promotes ovarian tumor growth. Sci Rep. 2014;4:3574. doi:10.1038/srep0357424389815
   PubMed Web of Science ®Google Scholar
• Kyriazoglou A, Liontos M, Ziogas DC, et al. Management of uterine sarcomas and prognostic indicators: real world data from a single-institution. BMC Cancer. 2018;18(1):1247. doi:10.1186/s12885-018-5156-130541504
   PubMed Web of Science ®Google Scholar
• Mollo A, Raffone A, Travaglino A, et al. Increased LDH5/LDH1 ratio in preoperative diagnosis of uterine sarcoma with inconclusive MRI and LDH total activity but suggestive CT scan: a case report. BMC Womens Health. 2018;18(1):169. doi:10.1186/s12905-018-0662-530340636
   PubMed Web of Science ®Google Scholar
• Abeler VM, Royne O, Thoresen S, Danielsen HE, Nesland JM, Kristensen GB. Uterine sarcomas in Norway. A histopathological and prognostic survey of a total population from 1970 to 2000 including 419 patients. Histopathology. 2009;54(3):355–364. doi:10.1111/j.1365-2559.2009.03231.x19236512
   PubMed Web of Science ®Google Scholar
• Deshmukh SP, Gonsalves CF, Guglielmo FF, Mitchell DG. Role of MR imaging of uterine leiomyomas before and after embolization. Radiographics. 2012;32(6):E251–281. doi:10.1148/rg.32612551723065174
   PubMed Web of Science ®Google Scholar
• Barral M, Place V, Dautry R, et al. Magnetic resonance imaging features of uterine sarcoma and mimickers. Abdom Radiol. 2017;42(6):1762–1772. doi:10.1007/s00261-017-1076-9
   PubMed Web of Science ®Google Scholar
• Devereaux KA, Schoolmeester JK. Smooth muscle tumors of the female genital tract. Surg Pathol Clin. 2019;12(2):397–455.  doi: 10.1016/j.path.2019.02.00431097110
   PubMedGoogle Scholar
• Glorie N, Baert T, Van Den Bosch T, Coosemans AN. Circulating protein biomarkers to differentiate uterine sarcomas from leiomyomas. Anticancer Res. 2019;39(8):3981–3989. doi:10.21873/anticanres.1355331366479
   PubMed Web of Science ®Google Scholar
• Saridogan E, Cutner A. Endoscopic management of uterine fibroids. Hum Fertil. 2006;9(4):201–208. doi:10.1080/14647270600560204
   Google Scholar
• Worldwide, AAGL Advancing Minimally Invasive Gynecology. AAGL practice report: morcellation during uterine tissue extraction. J Minim Invasive Gynecol. 2014;21(4):517–530. doi:10.1016/j.jmig.2014.05.01024865630
   PubMed Web of Science ®Google Scholar
• Harlow BL, Weiss NS, Lofton S. The epidemiology of sarcomas of the uterus. J Natl Cancer Inst. 1986;76(3):399–402.3456457
   PubMedGoogle Scholar
• Skorstad M, Kent A, Lieng M. Preoperative evaluation in women with uterine leiomyosarcoma. A nationwide cohort study. Acta Obstet Gynecol Scand. 2016;95(11):1228–1234. doi:10.1111/aogs.1300827564388
   PubMed Web of Science ®Google Scholar
• Van den Bosch T, Coosemans A, Morina M, Timmerman D, Amant F. Screening for uterine tumours. Best Pract Res Clin Obstet Gynaecol. 2012;26(2):257–266. doi:10.1016/j.bpobgyn.2011.08.00222078749
   PubMed Web of Science ®Google Scholar
• Shah SH, Jagannathan JP, Krajewski K, O’Regan KN, George S, Ramaiya NH. Uterine sarcomas: then and now. AJR Am J Roentgenol. 2012;199(1):213–223. doi:10.2214/AJR.11.728722733915
   PubMed Web of Science ®Google Scholar
• Huang GS, Chiu LG, Gebb JS, et al. Serum CA125 predicts extrauterine disease and survival in uterine carcinosarcoma. Gynecol Oncol. 2007;107(3):513–517. doi:10.1016/j.ygyno.2007.08.06017935762
   PubMed Web of Science ®Google Scholar
• Juang CM, Yen MS, Horng HC, Twu NF, Yu HC, Hsu WL. Potential role of preoperative serum CA125 for the differential diagnosis between uterine leiomyoma and uterine leiomyosarcoma. Eur J Gynaecol Oncol. 2006;27(4):370–374.17009628
   PubMed Web of Science ®Google Scholar
• Zhang Y, Qiao C, Li L, Zhao X, Li Y. Serum HE4 is more suitable as a biomarker than CA125 in Chinese women with benign gynecologic disorders. Afr Health Sci. 2014;14(4):913–918. doi:10.4314/ahs.v14i4.2025834501
   PubMed Web of Science ®Google Scholar
• Bayley JP, Devilee P. The Warburg effect in 2012. Curr Opin Oncol. 2012;24(1):62–67. doi:10.1097/CCO.0b013e32834deb9e22123234
   PubMed Web of Science ®Google Scholar
• Song KJ, Yu XN, Lv T, et al. Expression and prognostic value of lactate dehydrogenase-A and -D subunits in human uterine myoma and uterine sarcoma. Medicine. 2018;97(14):e0268. doi:10.1097/MD.000000000001026829620641
   PubMed Web of Science ®Google Scholar
• Jurisic V, Radenkovic S, Konjevic G. The actual role of LDH as tumor marker, biochemical and clinical aspects. Adv Exp Med Biol. 2015;867:115–124. doi:10.1007/978-94-017-7215-0_826530363
   PubMed Web of Science ®Google Scholar
• Kusunoki S, Terao Y, Ujihira T, et al. Efficacy of PET/CT to exclude leiomyoma in patients with lesions suspicious for uterine sarcoma on MRI. Taiwan J Obstet Gynecol. 2017;56(4):508–513. doi:10.1016/j.tjog.2017.05.00328805609
   PubMed Web of Science ®Google Scholar
• Nagai T, Takai Y, Akahori T, et al. Highly improved accuracy of the revised PREoperative sarcoma score (rPRESS) in the decision of performing surgery for patients presenting with a uterine mass. Springerplus. 2015;4:520. doi:10.1186/s40064-015-1318-726405640
   PubMedGoogle Scholar
• Karlsen NS, Karlsen MA, Hogdall CK, Hogdall EV. HE4 tissue expression and serum HE4 levels in healthy individuals and patients with benign or malignant tumors: a systematic review. Cancer Epidemiol Biomarkers Prev. 2014;23(11):2285–2295. doi:10.1158/1055-9965.EPI-14-044725169975
   PubMed Web of Science ®Google Scholar
• Mokhtar N, Thevarajah M, Ma N. Human epididymis protein 4 reference intervals in a multiethnic asian women population. Asian Pac J Cancer Prev. 2012;13(12):6391–6395. doi:10.7314/APJCP.2012.13.12.639123464464
   PubMedGoogle Scholar